I think we have to realize that a pharm such as PPHM is not going to walk into Goldman Sachs for their financing, and let's face it, it takes money to do what they are doing. They might have a great product, they might have a bust, but the major investment bankers are not about to bet on them at this point.
So we are faced with financing from these PIPEs for the immediate future, and it is an expensive way to finance. However, the alternatives are probably even more expensive.
If PPHM ultimately has no product, it won't matter how they financed their research, we investors are going to be big losers.
If they do have a blockbuster product, it won't matter either, as we investors are going to be big winners.
So why worry?
Market Data 
Markets 
AI
